stockrow
Friday 6 November 2026
Export IDXX’s income statement to Excel — free account
IDEXX Laboratories, Inc.
IDXX Healthcare Diagnostics & Research
IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.
- Revenue
- +9.86%
- EPS
- +17.3%
- Free cash flow
- +17.6%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
669.01
29.54
−4.23%
Follow IDXX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
34.99 | 36.74 | 41.01 | 51.33 |
+8 more quarters Free account |
P/S ratio |
8.83 | 9.13 | 10.07 | 12.64 | |
P/FCF ratio |
31.66 | 33.60 | 42.30 | 56.88 | |
P/Operating CF |
91.53 | 119.73 | 168.09 | 152.94 | |
P/B ratio |
22.02 | 25.78 | 28.76 | 33.89 | |
Price to Tangible BV |
37.05 | 37.67 | 43.06 | 50.31 | |
EV/Sales |
8.87 | 9.18 | 10.12 | 12.71 | |
EV/EBITDA |
24.84 | 25.93 | 28.94 | 36.33 | |
EV/Operating CF |
29.13 | 30.49 | 37.19 | 46.27 | |
EV/FCF |
31.80 | 33.80 | 42.53 | 57.16 | |
Quick Ratio |
0.64 | 0.64 | 0.62 | 0.64 | |
Current Ratio |
1.19 | 1.17 | 1.12 | 1.23 | |
Net Debt/EBITDA |
0.40 | 0.54 | 0.62 | 0.76 | |
Debt/Assets |
10.11% | 13.07% | 13.29% | 13.42% | |
Debt/Equity |
0.20 | 0.28 | 0.29 | 0.28 | |
Asset Turnover |
1.31 | 1.34 | 1.35 | 1.30 | |
Operating CF/Net income |
1.42 | 1.03 | 0.96 | 1.43 | |
Capex/Depreciation |
(0.71) | (0.65) | (0.90) | (0.77) | |
Interest Coverage |
53.94 | 41.80 | 46.84 | 34.27 | |
Research and Development Expense of Revenue |
5.67% | 5.38% | 5.77% | 6.13% | |
Selling, General and Administrative Expense of Revenue |
24.14% | 23.68% | 25.80% | 25.28% | |
Intangible Assets out of Total Assets |
0.20 | 0.15 | 0.15 | 0.16 | |
Share Based Compensation of Revenue |
1.34% | 1.32% | 1.43% | 1.48% | |
Graham Net Nets |
(0.01) | (0.01) | (0.01) | (0.01) | |
Graham Number |
89.23 | 81.15 | 77.60 | 76.94 | |
Earnings Yield |
2.86% | 2.72% | 2.44% | 1.95% | |
Free Cash Flow Yield |
3.16% | 2.98% | 2.36% | 1.76% | |
Revenue per Share |
15.40 | 15.41 | 14.32 | 13.56 | |
Operating CF per Share |
5.71 | 4.40 | 3.34 | 4.42 | |
Capex per Share |
(0.37) | (0.34) | (0.42) | (0.37) | |
Free Cash Flow per Share |
5.34 | 4.06 | 2.92 | 4.05 | |
Cash per Share |
2.51 | 2.49 | 2.52 | 2.24 | |
Shareholders Equity per Share |
23.71 | 20.42 | 19.54 | 19.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
23.71 | 20.42 | 19.54 | 19.96 | |
Free Cash Flow |
420.79 | 320.62 | 232.46 | 326.13 | |
Working Capital |
235.78 | 221.82 | 154.22 | 265.01 | |
Capital Expenditures |
(28.93) | (26.54) | (33.78) | (29.63) | |
Net Current Asset Value |
(337.93) | (320.27) | (375.32) | (331.55) | |
EV/EBIT |
27.45 | 28.67 | 32.01 | 40.21 | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.03 | |
Price to Operating Income |
27.33 | 28.50 | 31.83 | 40.01 | |
| Other line items | |||||
Average Receivables |
591.34 | 593.82 | 565.50 | 512.98 | |
Average Payables |
138.18 | 122.84 | 125.04 | 112.31 | |
Average Inventory |
391.22 | 392.08 | 389.19 | 379.82 | |
Average Assets |
3,546.91 | 3,386.56 | 3,299.59 | 3,322.10 | |
Average Common Equity |
1,715.18 | 1,535.70 | 1,502.06 | 1,600.35 |
Columns are period end dates · fundamentals updated 5 Nov 2026